Scancell Holdings plc, of Nottingham, U.K., announced formation of its core U.S. investigator team to lead a phase II checkpoint inhibitor combination study with its lead cancer vaccine, SCIB1. The study will assess the impact of adding SCIB1 to a checkpoint inhibitor in patients with late-stage melanoma. The aim will be to improve the objective response rates of anti-PD-1 monotherapy without adding toxicity. The trial is expected to enroll 80 stage 3/4 metastatic melanoma patients and commence in the second half of 2016, ending around 18 months later.